RxDoctor Payments Data

Albert Kao, MD

Nephrology · Daly City, CANPI 1225099286

Payments from drug & device makers

$1,708in general payments, 2019–2025

Across 85 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$392
  • Vifor Pharma, Inc.$312
  • AstraZeneca$215
  • Otsuka America Pharmaceutical, Inc.$162
  • Novo Nordisk$136
  • Johnson & Johnson$135
  • plus $357 from 8 others

What the payments were for

  • Food & beverage$1,69599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,708 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$430,437
Medicare patients
514
Services billed
2,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol275$397,536
VelphoroSucroferric Oxyhydroxide18$110,096
Sevelamer Carbonate94$66,718
JardianceEmpagliflozin32$43,810
VeltassaPatiromer Calcium Sorbitex22$34,673
DapagliflozinDapagliflozin Propanediol29$14,202
RetacritEpoetin Alfa-Epbx11$9,390
SpsSodium Polystyrene Sulfon/Sorb14$4,056
Atorvastatin Calcium271$3,954
Irbesartan156$3,637
Chlorthalidone182$3,129
ProsolParenteral Amino Acid 20% No.121$2,596
Calcium Acetate35$2,592
Amlodipine Besylate355$2,439
Bumetanide35$2,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$215$397,536275 claims
Fresenius USA Marketing, Inc.Velphoro$53$110,09618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,341 nephrology providers in California.

Other nephrology in Daly City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →